NCT05620940View on ClinicalTrials.gov

A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Opioid DependenceAlcohol DependenceMultiple Sclerosis
Interventions
DRUG

Vivitrol Injectable Product

Naltrexone Long-Acting Injection

DRUG

IVL3004

Naltrexone Long-Acting Injection

DRUG

IVL4002

Naltrexone Long-Acting Injection

Trial Locations (1)

4006

RECRUITING

Nucleus Network, Herston

Sponsors
All Listed Sponsors
lead

Inventage Lab., Inc.

INDUSTRY